Key points from article :
Cancer Research UK’s spinout, Achilles, raised $175.5 million to invest in the development of new cancer immunotherapies.
Cancer immunotherapies developed by Achilles are based on fundamental discoveries of how cancers develop and evolve.
Uses principles of tumour evolution to wind back the clock and pick out mutations that arose at the very early stages of cancer.
This allows to identify neoantigens present on all cancer cells within a tumour, known as clonal tumour neoantigens.
“We formed Achilles with Syncona to drive revolution in cancer treatment using clonal neoantigens to develop personalised T cell therapies,” - Tony Hickson, chief business officer for Cancer Research UK.
Two ongoing Phase 1/2a trials, including testing an immunotherapy...in patients with advanced non-small cell lung cancer and malignant melanoma that's come back or spread to other parts of the body.
Entered the world’s second largest stock market, NASDAQ, and is a strong indicator of the companies growing success.
